Hers vs CoreAgeRx: Wegovy brand vs flat-price GLP-1 plans
Quick verdict: Hers emphasizes FDA-approved, brand-name Wegovy with a personalized care team and no compounded medications, while CoreAgeRx emphasizes flat monthly pricing with no membership fee and set prices for semaglutide and tirzepatide.
Hers vs CoreAgeRx answers come down to whether you value brand-name, FDA-approved Wegovy with ongoing dose check-ins or a flat, no-membership price structure. Early verdict: choose Hers for FDA-approved Wegovy and a personalized care team; choose CoreAgeRx for predictable flat pricing and no membership fee.
Key difference 1: Pricing structure and membership
Hers lists Wegovy from $149/mo and notes membership requirements in its detailed description: an active Hers Weight Loss Membership is required, with a first-month fee of $39 and auto-renew at $149/month thereafter; membership and medication are billed separately and medication is not available without an active membership. CoreAgeRx emphasizes “Same Price. Every Month.” with no membership fee and specific monthly prices: semaglutide for $79/mo and tirzepatide for $129/mo. These are opposing models: Hers pairs brand-name pricing with a membership commitment, while CoreAgeRx promotes flat pricing and no membership.
Compare Hers pricing and membership
Key difference 2: Medication type, approval status, and compounding
Hers explicitly offers FDA-approved Wegovy, described as brand-name semaglutide and not a compounded medication. The Hers source reiterates that compounded medications are not FDA-approved and are not reviewed by FDA for safety, effectiveness or quality. CoreAgeRx lists semaglutide and tirzepatide pricing and dose limits on its landing page, but the captured CoreAgeRx content notes that medication-specific approval status must be confirmed and warns that branded and compounded products are not interchangeable. In short, Hers promotes an FDA-approved brand-name GLP-1; CoreAgeRx promotes pricing for semaglutide and tirzepatide with a note to confirm approval status.
Key difference 3: Care model and visit experience
Hers highlights a personalized care team with ongoing dose check-ins. CoreAgeRx promotes a 3-minute online visit and rapid sign-up messaging. That indicates Hers emphasizes ongoing clinician-reviewed dose monitoring and a care team, while CoreAgeRx emphasizes quick online visits and a streamlined, flat-price experience. Both state treatment is available only when a licensed clinician determines it is medically appropriate.
Key difference 4: Dosing options and price consistency
CoreAgeRx advertises dose limits: semaglutide up to 1.0 mg and tirzepatide up to 7.5 mg with the same monthly price every month and a claim of no price hikes as dose increases. Hers lists availability of high-dose semaglutide and other medications with varying starting prices, but also notes membership billing and that availability is subject to clinician review and state coverage. If dose flexibility and predictable billing matter, CoreAgeRx foregrounds flat pricing and dose caps; if brand options and clinician-managed dose check-ins matter, Hers emphasizes named-brand availability and ongoing monitoring.
Comparison table: Hers vs CoreAgeRx
| Criteria | Hers | CoreAgeRx |
|---|---|---|
| Starting price | Wegovy from $149/mo (membership required) | Semaglutide $79/mo, Tirzepatide $129/mo; same price every month |
| Membership | Active membership required; $39 first month, auto-renews $149/mo | No membership fee; no memberships |
| Medication type | FDA-approved brand-name Wegovy, not compounded | Semaglutide and tirzepatide offered; approval status must be confirmed |
| Care model | Personalized care team with ongoing dose check-ins | 3-minute online visit; streamlined sign-up |
| Dosing/pricing consistency | High-dose options available; pricing varies and tied to membership | Any dose up to limits; flat monthly price claimed |
Safety, regulatory notes, and availability
Both sources state treatment is available only when a licensed clinician determines it is medically appropriate. Hers explicitly notes that Ozempic is FDA-approved for type 2 diabetes and may be prescribed off-label for weight loss at a provider’s discretion, and that Wegovy and Zepbound are FDA-approved for weight loss. Hers reiterates that compounded medications are not FDA-approved and are not reviewed by FDA. CoreAgeRx captured content warns that medication-specific approval status must be confirmed and that branded and compounded products are not interchangeable. Both sources note that state availability, eligibility and prescription are subject to clinical review and may not be available in all states.
Start with Hers clinical review
Bottom line and how to choose
Hers vs CoreAgeRx comes down to priorities. Hers emphasizes FDA-approved, brand-name Wegovy, no compounded medications, and a personalized care team with ongoing dose check-ins, with pricing that involves a membership commitment. CoreAgeRx emphasizes predictable flat monthly pricing with no membership fee, explicit per-month prices for semaglutide and tirzepatide, and a fast online visit model. Both require clinician review and note that approval, eligibility and state availability are conditional.
Choose Hers if you prioritize FDA-approved Wegovy, brand-name medication and a personalized care team with ongoing dose check-ins and accept membership billing and the membership prerequisites.
Choose CoreAgeRx if you prioritize flat monthly pricing with no membership fee, set prices for semaglutide and tirzepatide and a rapid online visit experience, while confirming medication approval and eligibility.